ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2016

TP53 mutational status is predictive of pazopanib response in advanced sarcomas.

K Koehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.